Cosmos Health Comprehensive Income 2017-2024 | COSM

Cosmos Health comprehensive income from 2017 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

Cosmos Health Comprehensive Income 2017-2024 | COSM

Cosmos Health comprehensive income from 2017 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$80.6B
Takeda Pharmaceutical (TAK)$42.9B
Sandoz Group AG (SDZNY)$19.7B
Merck (MKKGY)$19.3B
Astellas Pharma (ALPMY)$18.3B
United Therapeutics (UTHR)$16.5B
Summit Therapeutics (SMMT)$14.2B
Neurocrine Biosciences (NBIX)$12.9B
Shionogi (SGIOY)$12.2B
Catalent (CTLT)$11.1B
Madrigal Pharmaceuticals (MDGL)$7.5B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$6.2B
Ionis Pharmaceuticals (IONS)$5.6B
Crinetics Pharmaceuticals (CRNX)$5.2B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Soleno Therapeutics (SLNO)$2.5B
Centessa Pharmaceuticals (CNTA)$2.3B
NewAmsterdam Pharma (NAMS)$1.9B
Xencor (XNCR)$1.8B
Evotec AG (EVO)$1.7B
Recursion Pharmaceuticals (RXRX)$1.7B
Guardian Pharmacy Services (GRDN)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.5B
Indivior (INDV)$1.5B
Harrow (HROW)$1.5B
Ocular Therapeutix (OCUL)$1.4B